These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 39036710)

  • 1. Trace amine-associated receptor 1 (TAAR1) agonism for psychosis: a living systematic review and meta-analysis of human and non-human data.
    Siafis S; Chiocchia V; Macleod MR; Austin C; Homiar A; Tinsdeall F; Friedrich C; Ramage FJ; Kennett J; Nomura N; Maksym O; Rutigliano G; Vano LJ; McCutcheon RA; Gilbert D; Ostinelli EG; Stansfield C; Dehdarirad H; Juma DO; Wright S; Simple O; Elugbadebo O; Tonia T; Mantas I; Howes OD; Furukawa TA; Milligan L; Moreno C; Elliott JH; Hastings J; Thomas J; Michie S; Sena ES; Seedat S; Egger M; Potts J; Cipriani A; Salanti G; Leucht S
    Wellcome Open Res; 2024; 9():182. PubMed ID: 39036710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Comparison of Ulotaront (SEP-363856) and Ralmitaront (RO6889450): Two TAAR1 Agonist Candidate Antipsychotics.
    Ågren R; Betari N; Saarinen M; Zeberg H; Svenningsson P; Sahlholm K
    Int J Neuropsychopharmacol; 2023 Sep; 26(9):599-606. PubMed ID: 37549917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.
    Siafis S; McCutcheon R; Chiocchia V; Ostinelli EG; Wright S; Stansfield C; Juma DO; Mantas I; Howes OD; Rutigliano G; Ramage F; Tinsdeall F; Friedrich C; Milligan L; Moreno C; Elliott JH; Thomas J; Macleod MR; Sena ES; Seedat S; Salanti G; Potts J; Cipriani A; Leucht S;
    Wellcome Open Res; 2023; 8():365. PubMed ID: 38634067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A New Treatment Paradigm: Targeting Trace Amine-Associated Receptor 1 (TAAR1) in Schizophrenia.
    Kane JM
    J Clin Psychopharmacol; 2022 Sep-Oct 01; 42(5 Suppl 1):S1-S13. PubMed ID: 36099402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies.
    Dedic N; Dworak H; Zeni C; Rutigliano G; Howes OD
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34947997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ulotaront: a TAAR1/5-HT1A agonist in clinical development for the treatment of schizophrenia.
    Højlund M; Correll CU
    Expert Opin Investig Drugs; 2022 Dec; 31(12):1279-1290. PubMed ID: 36533396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulotaront: review of preliminary evidence for the efficacy and safety of a TAAR1 agonist in schizophrenia.
    Achtyes ED; Hopkins SC; Dedic N; Dworak H; Zeni C; Koblan K
    Eur Arch Psychiatry Clin Neurosci; 2023 Oct; 273(7):1543-1556. PubMed ID: 37165101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.
    Mühlbauer V; Möhler R; Dichter MN; Zuidema SU; Köpke S; Luijendijk HJ
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013304. PubMed ID: 34918337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials.
    Le GH; Gillissie ES; Rhee TG; Cao B; Alnefeesi Y; Guo Z; Di Vincenzo JD; Jawad MY; March AM; Ramachandra R; Lui LMW; McIntyre RS
    Expert Opin Investig Drugs; 2023 May; 32(5):401-415. PubMed ID: 37096491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
    Dedic N; Wang L; Hajos-Korcsok E; Hecksher-Sørensen J; Roostalu U; Vickers SP; Wu S; Anacker C; Synan C; Jones PG; Milanovic S; Hopkins SC; Bristow LJ; Koblan KS
    Mol Metab; 2024 Feb; 80():101883. PubMed ID: 38237896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trace amine-associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders.
    Halff EF; Rutigliano G; Garcia-Hidalgo A; Howes OD
    Trends Neurosci; 2023 Jan; 46(1):60-74. PubMed ID: 36369028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiglucocorticoid and related treatments for psychosis.
    Garner B; Phillips LJ; Bendall S; Hetrick SE
    Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD006995. PubMed ID: 26725721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological interventions for people with borderline personality disorder.
    Stoffers-Winterling JM; Storebø OJ; Pereira Ribeiro J; Kongerslev MT; Völlm BA; Mattivi JT; Faltinsen E; Todorovac A; Jørgensen MS; Callesen HE; Sales CP; Schaug JP; Simonsen E; Lieb K
    Cochrane Database Syst Rev; 2022 Nov; 11(11):CD012956. PubMed ID: 36375174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Black Book of Psychotropic Dosing and Monitoring.
    DeBattista C; Schatzberg AF
    Psychopharmacol Bull; 2024 Jul; 54(3):8-59. PubMed ID: 38993656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological interventions for the treatment of disordered and problem gambling.
    Dowling N; Merkouris S; Lubman D; Thomas S; Bowden-Jones H; Cowlishaw S
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD008936. PubMed ID: 36130734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological interventions for somatoform disorders in adults.
    Kleinstäuber M; Witthöft M; Steffanowski A; van Marwijk H; Hiller W; Lambert MJ
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD010628. PubMed ID: 25379990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
    Milanović S; Dedic N; Lew R; Burton D; Koblan KS; Camilleri M; Hopkins SC
    Diabetes Obes Metab; 2024 Jun; 26(6):2466-2475. PubMed ID: 38533552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
    Yang SM; Ghoshal A; Hubbard JM; Gackière F; Teyssié R; Neale SA; Hopkins SC; Koblan KS; Bristow LJ; Dedic N
    Neuropsychopharmacology; 2024 Jun; 49(7):1091-1103. PubMed ID: 38110609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
    Heffernan MLR; Herman LW; Brown S; Jones PG; Shao L; Hewitt MC; Campbell JE; Dedic N; Hopkins SC; Koblan KS; Xie L
    ACS Med Chem Lett; 2022 Jan; 13(1):92-98. PubMed ID: 35047111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.